Eurizon Capital SGR S.p.A. Takes $6.48 Million Position in IQVIA Holdings Inc. $IQV

Eurizon Capital SGR S.p.A. purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, Holdings Channel.com reports. The fund purchased 28,736 shares of the medical research company’s stock, valued at approximately $6,482,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. purchased a new position in IQVIA during the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. boosted its position in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the fourth quarter worth approximately $27,000. Westside Investment Management Inc. boosted its position in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC acquired a new stake in shares of IQVIA in the third quarter worth approximately $30,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Up 2.7%

Shares of IQV stock opened at $187.14 on Tuesday. The stock has a market cap of $31.23 billion, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of 1.74 and a beta of 1.21. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a fifty-two week low of $136.41 and a fifty-two week high of $247.04. The firm’s 50 day moving average price is $170.76 and its two-hundred day moving average price is $195.83.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the previous year, the company posted $2.70 earnings per share. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has approved a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on IQV. Morgan Stanley set a $225.00 target price on shares of IQVIA in a research report on Thursday, May 7th. Royal Bank Of Canada began coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price on the stock. Citigroup reduced their price target on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Evercore reaffirmed an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Finally, Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $225.69.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.